Literature DB >> 17694574

The chemokine receptor CCR6 is an important component of the innate immune response.

Haitao Wen1, Cory M Hogaboam, Nicholas W Lukacs, Donald N Cook, Sergio A Lira, Steven L Kunkel.   

Abstract

In our initial studies we found that naïve CCR6-deficient (CCR6(-/-)) C57BL/6 mice possessed significantly lower number of both F4/80(+) macrophages and dendritic cells (DC), but higher number of B cells in the peritoneal cavity, as compared to naïve wild type (WT) controls. Furthermore, peritoneal macrophages isolated from CCR6(-/-) mice expressed significantly lower levels of inflammatory cytokines and nitric oxide following lipopolysaccharide (LPS)stimulation, as compared to WT macrophages. In a severe experimental peritonitis model induced by cecal ligation and puncture (CLP), CCR6(-/-) mice were protected when compared with WT controls. At 24 h following the induction of peritonitis, CCR6(-/-) mice exhibited significantly lower levels of inflammatory cytokines/chemokines in both the peritoneal cavity and blood. Interestingly, DC recruitment into the peritoneal cavity was impaired in CCR6(-/-) mice during the evolution of CLP-induced peritonitis. Peritoneal macrophages isolated from surviving CCR6(-/-) mice 3 days after CLP-induced peritonitis exhibited an enhanced LPS response compared with similarly treated WT peritoneal macrophages. These data illustrate that CCR6 deficiency alters the innate response via attenuating the hyperactive local and systemic inflammatory response during CLP-induced peritonitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17694574     DOI: 10.1002/eji.200737370

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Respiratory syncytial virus infection modifies and accelerates pulmonary disease via DC activation and migration.

Authors:  Sihyug Jang; Joost Smit; Lara E Kallal; Nicholas W Lukacs
Journal:  J Leukoc Biol       Date:  2013-01-04       Impact factor: 4.962

Review 2.  CCR6 as a mediator of immunity in the lung and gut.

Authors:  Toshihiro Ito; William F Carson; Karen A Cavassani; Judith M Connett; Steven L Kunkel
Journal:  Exp Cell Res       Date:  2011-03-10       Impact factor: 3.905

Review 3.  The biology of chemokines and their receptors.

Authors:  Sergio A Lira; Glaucia C Furtado
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

4.  CCR6 expression reduces mouse survival upon malarial challenge with Plasmodium berghei NK65 strain.

Authors:  Eduardo Lani Volpe da Silveira; Urvashi Rai; Vivian Bonezi; Carlos Rodrigo Zárate-Bladés; Carla Claser
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-06-17       Impact factor: 2.747

5.  CCR6 controls autoimmune but not innate immunity-driven experimental arthritis.

Authors:  Michael Bonelli; Antonia Puchner; Lisa Göschl; Silvia Hayer; Birgit Niederreiter; Guenter Steiner; Katharina Tillmann; Roberto Plasenzotti; Bruno Podesser; Philippe Georgel; Josef Smolen; Clemens Scheinecker; Stephan Blüml
Journal:  J Cell Mol Med       Date:  2018-08-22       Impact factor: 5.310

6.  Potential roles of CCR5(+) CCR6(+) dendritic cells induced by nasal ovalbumin plus Flt3 ligand expressing adenovirus for mucosal IgA responses.

Authors:  Yoshiko Fukuyama; Daisuke Tokuhara; Shinichi Sekine; Kazuyoshi Aso; Kosuke Kataoka; Julia Davydova; Masato Yamamoto; Rebekah S Gilbert; Yuka Tokuhara; Keiko Fujihashi; Jun Kunisawa; Yoshikazu Yuki; Hiroshi Kiyono; Jerry R McGhee; Kohtaro Fujihashi
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

7.  A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer.

Authors:  Valerie F Curtis; Hui Wang; Pengyuan Yang; Roger E McLendon; Xiaohan Li; Qun-Yong Zhou; Xiao-Fan Wang
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

8.  Leukocyte attraction by CCL20 and its receptor CCR6 in humans and mice with pneumococcal meningitis.

Authors:  Matthias Klein; Matthijs C Brouwer; Barbara Angele; Madelijn Geldhoff; Gabriel Marquez; Rosa Varona; Georg Häcker; Helga Schmetzer; Hans Häcker; Sven Hammerschmidt; Arie van der Ende; Hans-Walter Pfister; Diederik van de Beek; Uwe Koedel
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

9.  Acetamidine-Based iNOS Inhibitors as Molecular Tools to Counteract Inflammation in BV2 Microglial Cells.

Authors:  Silvia Grottelli; Rosa Amoroso; Lara Macchioni; Fiorella D'Onofrio; Katia Fettucciari; Ilaria Bellezza; Cristina Maccallini
Journal:  Molecules       Date:  2020-06-06       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.